Join our panel of experts for a dynamic discussion on the future of imaging, biomarker validation, and clinical trial innovation in pulmonary diseases.

Pulmonary research is advancing rapidly, yet clinical trials in rare and progressive lung diseases continue to face a fundamental challenge: how do we measure disease consistently, confidently, and in ways regulators can trust?

This session will examine how variability in imaging interpretation, measurement approaches, and endpoint definitions can influence clinical trial outcomes, biomarker qualification, and regulatory decision-making. Although imaging is central to understanding pulmonary disease, it has not yet achieved consistent validation as a trusted biomarker across studies, institutions, and therapeutic areas.

Bringing together leaders in radiology, pulmonology, pathology, and clinical research, this discussion will explore how the field can move from variability to validation by improving standardization, reproducibility, and evidence generation.

The session will also introduce the next phase of work from the OSIC, including expanded longitudinal datasets and the launch of the OSIC Cooperative Research Network (OCRN) — a disease-agnostic, shared research infrastructure designed to support scalable, cross-disease studies and regulatory-aligned evidence generation.

Join us for a focused conversation on how imaging can be reframed as a coordinate system for disease — helping improve clinical trial design, strengthen biomarker validation, and ultimately accelerate better outcomes for patients.